Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways

[1]  A. Berger,et al.  RAF inhibition overcomes resistance to TRAIL-induced apoptosis in melanoma cells. , 2014, The Journal of investigative dermatology.

[2]  L. Andĕra,et al.  Multi-level disruption of the extrinsic apoptotic pathway mediates resistance of leukemia cells to TNF-related apoptosis-inducing ligand (TRAIL). , 2013, Neoplasma.

[3]  T. Kaufmann,et al.  TRAIL enhances paracetamol-induced liver sinusoidal endothelial cell death in a Bim- and Bid-dependent manner , 2012, Cell Death and Disease.

[4]  B. Widemann,et al.  Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Fulda,et al.  Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP , 2012, Oncogene.

[6]  C. Croce,et al.  MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non–small-cell lung cancer through BIM down-regulation , 2012, Proceedings of the National Academy of Sciences.

[7]  V. A. Flørenes,et al.  Dacarbazine and the Agonistic TRAIL Receptor-2 Antibody Lexatumumab Induce Synergistic Anticancer Effects in Melanoma , 2012, PloS one.

[8]  G. Tomlinson,et al.  The Transcription Factor Wilms Tumor 1 Confers Resistance in Myeloid Leukemia Cells against the Proapoptotic Therapeutic Agent TRAIL (Tumor Necrosis Factor α-related Apoptosis-inducing Ligand) by Regulating the Antiapoptotic Protein Bcl-xL* , 2012, The Journal of Biological Chemistry.

[9]  Xia Jing,et al.  Targeted Inhibition of Src Kinase with Dasatinib Blocks Thyroid Cancer Growth and Metastasis , 2012, Clinical Cancer Research.

[10]  Ahmedin Jemal,et al.  Cancers with increasing incidence trends in the United States: 1999 through 2008 , 2012, CA: a cancer journal for clinicians.

[11]  C. Montagna,et al.  Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors , 2011, Oncotarget.

[12]  B. Bonavida,et al.  Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis , 2011, Cell cycle.

[13]  L. Andĕra,et al.  Selective BRAFV600E Inhibitor PLX4720, Requires TRAIL Assistance to Overcome Oncogenic PIK3CA Resistance , 2011, PloS one.

[14]  W. El-Deiry,et al.  Off-Target Lapatinib Activity Sensitizes Colon Cancer Cells Through TRAIL Death Receptor Up-Regulation , 2011, Science Translational Medicine.

[15]  V. Cryns,et al.  Enhanced Metastasis Suppression by Targeting TRAIL Receptor 2 in a Murine Model of Triple-Negative Breast Cancer , 2011, Clinical Cancer Research.

[16]  M. McMahon,et al.  Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse. , 2011, Cancer research.

[17]  A. Aplin,et al.  Mechanisms of resistance to RAF inhibitors in melanoma , 2011, The Journal of investigative dermatology.

[18]  A. Fischer,et al.  Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer , 2011, The oncologist.

[19]  S. Fulda,et al.  Targeting Aberrant PI3K/Akt Activation by PI103 Restores Sensitivity to TRAIL-Induced Apoptosis in Neuroblastoma , 2011, Clinical Cancer Research.

[20]  Xiangxuan Zhao,et al.  Reactive Oxygen Species Is Essential for Cycloheximide to Sensitize Lexatumumab-Induced Apoptosis in Hepatocellular Carcinoma Cells , 2011, PloS one.

[21]  C. Nucera,et al.  Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer. , 2010, Surgery.

[22]  C. Nucera,et al.  The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? , 2010, Oncotarget.

[23]  Michael Peyton,et al.  Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo , 2010, PloS one.

[24]  W. El-Deiry,et al.  TRAIL receptor signaling and therapeutics , 2010, Expert opinion on therapeutic targets.

[25]  A. Aplin,et al.  Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. , 2010, Cancer research.

[26]  H. Wakelee,et al.  Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  M. Santoro,et al.  Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. , 2009, The Journal of clinical endocrinology and metabolism.

[28]  C. Nucera,et al.  A novel orthotopic mouse model of human anaplastic thyroid carcinoma. , 2009, Thyroid : official journal of the American Thyroid Association.

[29]  B. Nelkin,et al.  Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. , 2009, The Journal of clinical endocrinology and metabolism.

[30]  S. Wesselborg,et al.  The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL‐induced apoptosis , 2009, International journal of cancer.

[31]  R. Khosravi‐Far,et al.  A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. , 2009, Cancer research.

[32]  Y. Kakehi,et al.  Enhancement of Lexatumumab-Induced Apoptosis in Human Solid Cancer Cells by Cisplatin in Caspase-Dependent Manner , 2009, Clinical Cancer Research.

[33]  S. Fulda.  Tumor resistance to apoptosis , 2009, International journal of cancer.

[34]  J. Copland,et al.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. , 2008, Endocrine-related cancer.

[35]  A. Pinchera,et al.  BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. , 2008, The Journal of clinical endocrinology and metabolism.

[36]  J. Milot,et al.  Increased p53 level, Bax/Bcl-x(L) ratio, and TRAIL receptor expression in human emphysema. , 2008, American journal of respiratory and critical care medicine.

[37]  M. Loda,et al.  BRAF(V600E) mutation and the biology of papillary thyroid cancer. , 2008, Endocrine-related cancer.

[38]  M. Xing,et al.  BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. , 2007, Endocrine reviews.

[39]  R. Plummer,et al.  Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers , 2007, Clinical Cancer Research.

[40]  Xiaoping Zhang,et al.  Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. , 2007, Cancer letters.

[41]  D. McMillin,et al.  Targeting BRAFV600E in thyroid carcinoma: therapeutic implications , 2007, Molecular Cancer Therapeutics.

[42]  E. Baudin,et al.  New therapeutic approaches for metastatic thyroid carcinoma. , 2007, The Lancet. Oncology.

[43]  David E. Misek,et al.  Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis , 2005, Oncogene.

[44]  Xiaobo Cao,et al.  Enhancing TRAIL-induced apoptosis by Bcl-XL siRNA , 2005, Cancer biology & therapy.

[45]  E. Borden,et al.  Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis , 2004, Cell Death and Differentiation.

[46]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[47]  A. Ruggeri,et al.  A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells , 2003, Leukemia.

[48]  Z. Ronai,et al.  Death receptors and melanoma resistance to apoptosis , 2003, Oncogene.

[49]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[50]  H. Kalthoff,et al.  Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis , 2000, Oncogene.

[51]  Shinichiro,et al.  Carcinoma , 1906, The Hospital.